DGAP-News

MagForce AG Publishes Shareholder Letter

DGAP-News: MagForce AG / Key word(s): Miscellaneous MagForce AG Publishes Shareholder Letter 21.09.2020 / 08:45 The issuer is solely responsible for the content of this announcement. MagForce AG Publishes Shareholder Letter

• Europe: Continued significantly increased numbers of brain tumor treatments
• USA: Treatments of patients in current stage of the prostate cancer trial with streamlined protocol so far show only minimal treatment-related side effects

Berlin, Germany, and Nevada, USA, September 21, 2020 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today published a Shareholder Letter:

"Dear MagForce Shareholders,

I am very pleased to update you on the progress we have made with our transformative NanoTherm therapy system as a treatment option for solid tumors. Although the COVID-19 pandemic has developed into a very serious global healthcare challenge with extreme economic and personal restricitons, MagForce is coping with the evolving situation and we continue to have very good prospects for 2020. Our utmost priority in this pandemic remains the safety of our employees, patients and physicians in the clinics as well as partners. We are still happy to say that MagForce's production has barely been affected. Our expert team is diligently working to bring our therapeutic system to cancer patients worldwide.

MagForce AG - Europe - Brain Cancer Treatment:

Despite the challenging COVID-19 situation, our commercial team was able to turn the corner on commercial revenues and I am very proud to inform you that this has now been impressively reflected in treatment figures. We have won partner clinics that are convinced of our technology and use it with great commitment. We see that this trend is so far sustainable and more and more patients, who often do not have time to spare, have access to our innovative brain tumor treatment option.